Gadoteridol
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | IV |
ATC code | V08CA04 (WHO) |
Legal status | |
Legal status |
|
Identifiers | |
| |
Synonyms | (10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3−)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium |
CAS Number |
120066-54-8 ![]() |
PubChem (CID) | 60714 |
DrugBank |
DB00597 ![]() |
ChemSpider |
54719 ![]() |
UNII |
0199MV609F ![]() |
KEGG |
D01137 ![]() |
ChEBI |
CHEBI:31643 ![]() |
ChEMBL |
CHEMBL1200593 ![]() |
Chemical and physical data | |
Formula | C17H29GdN4O7 |
Molar mass | 558.68 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
![]() ![]() |
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.
References
- Bracco Diagnostic Inc. (May 2007). "Gadoteridol (ProHance) prescribing information (revised May 2007)". DailyMed. U.S. National Library of Medicine. Retrieved 2008-07-13.
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.